Clinical trials: Hepatitis B, completed
Hepatitis C, Chronic, HIV Infection
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
This phase II, multicentric, national pilot trial is designed to estimate the sustained virological response rate (SVR) following a 12 weeks treatment by telaprevir combined with a 48 or 72 weeks treatment by peginterferon and…
- Trial name
- TelapreVIH (NCT01332955)
- Testing
- Telaprevir, pegIFN alfa-2a, Ribavirin
- Where
- France
- Volunteers
- 70 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Liver Fibrosis
Development of Non-Invasive MRI Applications for Liver Fibrosis and Inflammation
Chronic liver disease is a major healthcare problem in Hong Kong and worldwide. The diagnosis of liver fibrosis and inflammation in patients with chronic liver disease has important prognostic and therapeutic implications.
- Trial name
- NCT05168982
- Where
- Hong Kong
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
HIV Infections, Hepatitis C Virus Infection
Digital Community to Improve Health in Rural Areas
The study is a cluster randomized controlled trial developed in counties located in Appalachia and the Midwest. We will prioritize counties from states with high risk for HIV and HCV infection associated with injection drug use.
- Trial name
- NCT05363865
- Testing
- Virtual Community Intervention, Standard of Care
- Where
- United States
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HCV, HIV
KP-Led Same Day HCV Test and Treat Study
This is a Hybrid design to primarily assess effectiveness, and to secondarily observe and collect data on the implementation of the service.
- Trial name
- 479/65 (NCT05479760)
- Testing
- KP-Led HCV test and treat service
- Where
- 4 sites in Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute of HIV Research and Innovation Foundation, Thailand
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Chronic Hepatitis B Virus (Hbv)
Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)
Background: People who were born outside of the country are the largest group of adults infected with chronic hepatitis B virus (HBV) in the US. HBV affects the liver.
- Trial name
- NCT05621304
- Where
- 2 sites in United States
- Volunteers
- 274 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Autoimmune Hepatitis
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
VAY736 dose testing; VAY736 efficacy and safety testing.
- Trial name
- AMBER (NCT03217422)
- Testing
- VAY736
- Where
- 28 sites in United States, Argentina and 8 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Vertical Transmission of Infectious Disease
The COMBAT HBV Feasibility Trial
This is a double-blind, randomized placebo-controlled trial (RCT) of a prophylaxis-for-all approach to prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV) in the Democratic Republic of Congo (DRC).
- Trial name
- COMBAT-HBV (NCT05705427)
- Testing
- Tenofovir Disoproxil Fumarate 300 MG, Hepatitis B monovalent vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 317 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis B, Haemophilus Influenzae Type b Immunisation
Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
Primary objectives: To investigate the incidence of adverse events occurred following administration of Hexaxim in infants from 2 months of age under routine clinical practice, as per approved indications
- Trial name
- NCT06793826
- Testing
- DTaP-IPV-Hep B-PRP-T combined vaccine
- Where
- 2 sites in South Korea
- Volunteers
- 713 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Opioid Dependence, Addiction
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
The purpose of this study is to conduct empiric studies of tuberculosis (TB) among people in prison with and without a history of opioid dependence.
- Conditions
- Opioid Dependence, Addiction, HIV/AIDS, Tuberculosis
- Trial name
- HARAPAN II (NCT03089983)
- Testing
- Isoniazid, Rifapentine
- Where
- Malaysia
- Volunteers
- 316 people
- Sponsor
- Yale University
Intravenous Drug Usage, HIV/AIDS
Building on Needle Exchange to Optimize Prevention & Treatment
There are several biomedical interventions that can help people who inject drugs (particularly those with or at risk for HIV), but these services often do not get to the people most in need.
- Trial name
- NCT03567174
- Testing
- Integrated care van (ICV)
- Where
- United States
- Volunteers
- 720 people
- Sponsor
- Johns Hopkins University
Hepatitis B, Chronic
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
- Trial name
- NCT05612581
- Testing
- VIR-3434, VIR-2218, TDF
- Where
- 15 sites in France, Hong Kong and 4 more
- Volunteers
- 33 people
- Sponsor
- Vir Biotechnology, Inc.
Chronic Hepatitis B
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
- Trial name
- NCT05770895
- Testing
- GS-2829, GS-6779
- Where
- 9 sites in New Zealand, Taiwan
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
HBV, Alcoholic Hepatitis
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
The purpose of this study is to recruit a random and representative sample of individuals within several Zambian communities for markers of Hepatitis B Virus (HBV) and to characterize chronic HBV infection and indications for…
- Conditions
- HBV, Alcoholic Hepatitis, Liver Fibroses
- Trial name
- HEP-ZED (NCT03149627)
- Testing
- Estimates - prevalence of lifetime/chronic HBV infection
- Where
- Zambia
- Volunteers
- 5,003 people
- Sponsor
- University of Alabama at Birmingham
Hepatitis B
Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children
The main objective of this study is to compare the immunogenicity of the hepatitis B component in children vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12 months of age versus (II) one dose of…
- Trial name
- NCT04294433
- Testing
- Infanrix-hexa, Infanrix-hexa and Twinrix Junior
- Where
- 2 sites in Canada
- Volunteers
- 431 people, healthy volunteers welcome
- Sponsor
- Laval University
Hepatitis B
A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
This study is conducted to assess safety and immunogenicity of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system in healthy, HBs naïve, adults aged 18-45 years and to differentiate GSK's AS37 adjuvant system from…
- Trial name
- NCT05561673
- Testing
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system, GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
- Where
- 5 sites in Belgium, Germany and 1 more
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Autoimmune Hepatitis
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period…
- Trial name
- NCT05569759
- Testing
- zetomipzomib, zetomipzomib in open-label extension
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kezar Life Sciences, Inc.
Chronic Hepatitis C
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan.
- Trial name
- NCT00200343
- Testing
- Ursodeoxycholic acid 150mg / day, Ursodeoxycholic acid 600mg / day, Ursodeoxycholic acid 900mg / day
- Where
- Japan
- Volunteers
- 596 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Hepatitis C
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00591214
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00621296
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Tanabe Pharma Corporation